Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups.

Mohamed ME, Schladt DP, Guan W, Wu B, van Setten J, Keating BJ, Iklé D, Remmel RP, Dorr CR, Mannon RB, Matas AJ, Israni AK, Oetting WS, Jacobson PA; DeKAF Genomics and GEN03 Investigators.

Am J Transplant. 2019 Apr 6. doi: 10.1111/ajt.15385. [Epub ahead of print]

PMID:
30953600
2.

The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population.

Stapleton CP, Heinzel A, Guan W, van der Most PJ, van Setten J, Lord GM, Keating BJ, Israni AK, de Borst MH, Bakker SJL, Snieder H, Weale ME, Delaney F, Hernandez-Fuentes MP, Reindl-Schwaighofer R, Oberbauer R, Jacobson PA, Mark PB, Chapman FA, Phelan PJ, Kennedy C, Sexton D, Murray S, Jardine A, Traynor JP, McKnight AJ, Maxwell AP, Smyth LJ, Oetting WS, Matas AJ, Mannon RB, Schladt DP, Iklé DN, Cavalleri GL, Conlon PJ; UK Ireland Renal Transplant Consortium; DeKAF Genomics and GEN03 Studies; International Genetics and Translational Research in Transplantation Network.

Am J Transplant. 2019 Feb 27. doi: 10.1111/ajt.15326. [Epub ahead of print]

PMID:
30920136
3.

Comparative Evaluation of Median Versus Youden Index Dichotomization Methods: Exposure-Response Analysis of Mycophenolic Acid and Acyl-Glucuronide Metabolite.

Okour M, Jacobson PA, Israni A, Brundage RC.

Eur J Drug Metab Pharmacokinet. 2019 Mar 16. doi: 10.1007/s13318-019-00550-2. [Epub ahead of print]

PMID:
30879263
4.

Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies.

Oetting WS, Wu B, Schladt DP, Guan W, van Setten J, Keating BJ, Iklé D, Remmel RP, Dorr CR, Mannon RB, Matas AJ, Israni AK, Jacobson PA; DeKAF Genomics and GEN-03 Investigators.

Transplantation. 2019 Jun;103(6):1131-1139. doi: 10.1097/TP.0000000000002625.

PMID:
30801552
5.

Analysis of 75 Candidate SNPs Associated with Acute Rejection in Kidney Transplant Recipients: Validation of rs2910164 in MicroRNA MIR146A.

Oetting WS, Schladt DP, Dorr CR, Wu B, Guan W, Remmel RP, Iklé D, Mannon RB, Matas AJ, Israni AK, Jacobson PA; DeKAF Genomics and GEN03 Investigators.

Transplantation. 2019 Feb 11. doi: 10.1097/TP.0000000000002659. [Epub ahead of print]

PMID:
30801535
6.

Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit.

Zhou S, Skaar DJ, Jacobson PA, Huang RS.

Front Pharmacol. 2018 Dec 4;9:1436. doi: 10.3389/fphar.2018.01436. eCollection 2018. Review.

7.

Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing.

Dorr CR, Wu B, Remmel RP, Muthusamy A, Schladt DP, Abrahante JE, Guan W, Mannon RB, Matas AJ, Oetting WS, Jacobson PA, Israni AK; for DeKAF Genomics.

Pharmacogenomics J. 2018 Nov 16. doi: 10.1038/s41397-018-0063-z. [Epub ahead of print]

8.

Urinary microbiome associated with chronic allograft dysfunction in kidney transplant recipients.

Wu JF, Muthusamy A, Al-Ghalith GA, Knights D, Guo B, Wu B, Remmel RP, Schladt DP, Alegre ML, Oetting WS, Jacobson PA, Israni AK.

Clin Transplant. 2018 Dec;32(12):e13436. doi: 10.1111/ctr.13436. Epub 2018 Nov 18.

PMID:
30372560
9.

Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.

Seibert SR, Schladt DP, Wu B, Guan W, Dorr C, Remmel RP, Matas AJ, Mannon RB, Israni AK, Oetting WS, Jacobson PA.

Clin Transplant. 2018 Dec;32(12):e13424. doi: 10.1111/ctr.13424. Epub 2018 Oct 31.

PMID:
30318646
10.

Tacrolimus Elimination in Four Patients With a CYP3A5*3/*3 CYP3A4*22/*22 Genotype Combination.

Scheibner A, Remmel R, Schladt D, Oetting WS, Guan W, Wu B, Dorr C, Israni A, Jacobson PA.

Pharmacotherapy. 2018 May 26. doi: 10.1002/phar.2131. [Epub ahead of print]

PMID:
29804290
11.

NPHP1 (Nephrocystin-1) Gene Deletions Cause Adult-Onset ESRD.

Snoek R, van Setten J, Keating BJ, Israni AK, Jacobson PA, Oetting WS, Matas AJ, Mannon RB, Zhang Z, Zhang W, Hao K, Murphy B, Reindl-Schwaighofer R, Heinzl A, Oberbauer R, Viklicky O, Conlon PJ, Stapleton CP, Bakker SJL, Snieder H, Peters EDJ, van der Zwaag B, Knoers NVAM, de Borst MH, van Eerde AM.

J Am Soc Nephrol. 2018 Jun;29(6):1772-1779. doi: 10.1681/ASN.2017111200. Epub 2018 Apr 13.

12.

Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure.

Okour M, Jacobson PA, Ahmed MA, Israni AK, Brundage RC.

J Clin Pharmacol. 2018 May;58(5):628-639. doi: 10.1002/jcph.1064. Epub 2018 Jan 12.

13.

Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.

Oetting WS, Wu B, Schladt DP, Guan W, Remmel RP, Dorr C, Mannon RB, Matas AJ, Israni AK, Jacobson PA.

Pharmacogenomics. 2018 Feb;19(3):175-184. doi: 10.2217/pgs-2017-0187. Epub 2018 Jan 10.

14.

Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients.

Oetting WS, Wu B, Schladt DP, Guan W, Remmel RP, Mannon RB, Matas AJ, Israni AK, Jacobson PA.

Pharmacogenomics J. 2018 May 22;18(3):501-505. doi: 10.1038/tpj.2017.49. Epub 2017 Nov 21.

PMID:
29160300
15.

Concepts of Genomics in Kidney Transplantation.

Oetting WS, Dorr C, Remmel RP, Matas AJ, Israni AK, Jacobson PA.

Curr Transplant Rep. 2017 Jun;4(2):116-123. doi: 10.1007/s40472-017-0153-x. Epub 2017 May 24.

16.

Genetics of acute rejection after kidney transplantation.

Dorr CR, Oetting WS, Jacobson PA, Israni AK.

Transpl Int. 2018 Mar;31(3):263-277. doi: 10.1111/tri.13084. Epub 2017 Nov 8. Review.

17.

Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.

Yanik MV, Irvin MR, Beasley TM, Jacobson PA, Julian BA, Limdi NA.

Pharmacotherapy. 2017 Nov;37(11):1366-1373. doi: 10.1002/phar.2032. Epub 2017 Nov 2.

18.

CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism.

Dorr CR, Remmel RP, Muthusamy A, Fisher J, Moriarity BS, Yasuda K, Wu B, Guan W, Schuetz EG, Oetting WS, Jacobson PA, Israni AK.

Drug Metab Dispos. 2017 Aug;45(8):957-965. doi: 10.1124/dmd.117.076307. Epub 2017 May 22.

19.

Validation Is Critical for Genome-Wide Association Study-Based Associations.

Oetting WS, Jacobson PA, Israni AK.

Am J Transplant. 2017 Feb;17(2):318-319. doi: 10.1111/ajt.14051. Epub 2016 Oct 12. No abstract available.

20.

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.

Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, Jacobson PA, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2025-2030. doi: 10.1016/j.bbmt.2016.08.005. Epub 2016 Aug 9.

21.

Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.

Liang S, Brundage RC, Jacobson PA, Blaes A, Kirstein MN.

Br J Clin Pharmacol. 2016 Sep;82(3):773-83. doi: 10.1111/bcp.12989. Epub 2016 Jun 3.

22.

Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.

Sanghavi K, Wiseman A, Kirstein MN, Cao Q, Brundage R, Jensen K, Rogosheske J, Kurtzweil A, Long-Boyle J, Wagner J, Warlick ED, Brunstein CG, Weisdorf DJ, Jacobson PA.

Transl Res. 2016 Sep;175:103-115.e4. doi: 10.1016/j.trsl.2016.03.017. Epub 2016 Mar 31.

23.

Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient.

Wasko JA, Westholder JS, Jacobson PA.

J Oncol Pharm Pract. 2017 Jan;23(1):75-79. doi: 10.1177/1078155215624263. Epub 2016 Jul 8.

PMID:
26763003
24.

Genotype-guided tacrolimus dosing in African-American kidney transplant recipients.

Sanghavi K, Brundage RC, Miller MB, Schladt DP, Israni AK, Guan W, Oetting WS, Mannon RB, Remmel RP, Matas AJ, Jacobson PA.

Pharmacogenomics J. 2017 Jan;17(1):61-68. doi: 10.1038/tpj.2015.87. Epub 2015 Dec 15.

25.

Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.

Oetting WS, Schladt DP, Guan W, Miller MB, Remmel RP, Dorr C, Sanghavi K, Mannon RB, Herrera B, Matas AJ, Salomon DR, Kwok PY, Keating BJ, Israni AK, Jacobson PA; DeKAF Investigators.

Am J Transplant. 2016 Feb;16(2):574-82. doi: 10.1111/ajt.13495. Epub 2015 Oct 20.

26.

Concept and design of a genome-wide association genotyping array tailored for transplantation-specific studies.

Li YR, van Setten J, Verma SS, Lu Y, Holmes MV, Gao H, Lek M, Nair N, Chandrupatla H, Chang B, Karczewski KJ, Wong C, Mohebnasab M, Mukhtar E, Phillips R, Tragante V, Hou C, Steel L, Lee T, Garifallou J, Guettouche T, Cao H, Guan W, Himes A, van Houten J, Pasquier A, Yu R, Carrigan E, Miller MB, Schladt D, Akdere A, Gonzalez A, Llyod KM, McGinn D, Gangasani A, Michaud Z, Colasacco A, Snyder J, Thomas K, Wang T, Wu B, Alzahrani AJ, Al-Ali AK, Al-Muhanna FA, Al-Rubaish AM, Al-Mueilo S, Monos DS, Murphy B, Olthoff KM, Wijmenga C, Webster T, Kamoun M, Balasubramanian S, Lanktree MB, Oetting WS, Garcia-Pavia P, MacArthur DG, de Bakker PI, Hakonarson H, Birdwell KA, Jacobson PA, Ritchie MD, Asselbergs FW, Israni AK, Shaked A, Keating BJ.

Genome Med. 2015 Oct 1;7:90. doi: 10.1186/s13073-015-0211-x.

27.

Multigene predictors of tacrolimus exposure in kidney transplant recipients.

Pulk RA, Schladt DS, Oetting WS, Guan W, Israni AK, Matas AJ, Remmel RP, Jacobson PA; DeKAF Investigators.

Pharmacogenomics. 2015 Jul;16(8):841-54. doi: 10.2217/pgs.15.42. Epub 2015 Jun 12.

28.

Differentially expressed gene transcripts using RNA sequencing from the blood of immunosuppressed kidney allograft recipients.

Dorr C, Wu B, Guan W, Muthusamy A, Sanghavi K, Schladt DP, Maltzman JS, Scherer SE, Brott MJ, Matas AJ, Jacobson PA, Oetting WS, Israni AK.

PLoS One. 2015 May 6;10(5):e0125045. doi: 10.1371/journal.pone.0125045. eCollection 2015.

29.

Telomere length of recipients and living kidney donors and chronic graft dysfunction in kidney transplants.

Oetting WS, Guan W, Schladt DP, Wildebush WA, Becker J, Thyagarajan B, Jacobson PA, Matas AJ, Israni AK.

Transplantation. 2014 Feb 15;97(3):325-9. doi: 10.1097/01.TP.0000436705.87898.88.

30.

Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics.

Israni AK, Riad SM, Leduc R, Oetting WS, Guan W, Schladt D, Matas AJ, Jacobson PA; DeKAF Genomics Investigators.

Transpl Int. 2013 Oct;26(10):982-9. doi: 10.1111/tri.12155. Epub 2013 Jul 24.

31.

Transplant rejection and risk: in search of the genetic dark matter.

Oetting WS, Jacobson PA, Israni AK.

J Gastrointestin Liver Dis. 2013 Jun;22(2):125-6. No abstract available.

32.

Inflammation in the setting of chronic allograft dysfunction post-kidney transplant: phenotype and genotype.

Israni AK, Leduc R, Jacobson PA, Wildebush W, Guan W, Schladt D, Matas AJ, Oetting WS; DeKAF Genomics Investigators.

Clin Transplant. 2013 May-Jun;27(3):348-58. doi: 10.1111/ctr.12074. Epub 2013 Jan 27.

33.

Donor polymorphisms of toll-like receptor 4 associated with graft failure in liver transplant recipients.

Oetting WS, Guan W, Schladt DP, Leduc RE, Jacobson PA, Matas AJ, Chinnakotla S, Schröppel B, Murphy BT, Israni AK.

Liver Transpl. 2012 Dec;18(12):1399-405. doi: 10.1002/lt.23549.

34.

Obesity effects on cyclophosphamide-induced DNA damage in hematopoietic cell transplant recipients.

Johnson LA, Tretyakova N, Jacobson PA.

In Vivo. 2012 Sep-Oct;26(5):853-7.

PMID:
22949601
35.

Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs.

Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A.

Am J Transplant. 2012 Dec;12(12):3326-36. doi: 10.1111/j.1600-6143.2012.04232.x. Epub 2012 Sep 4.

36.

Validation of tacrolimus equation to predict troughs using genetic and clinical factors.

Passey C, Birnbaum AK, Brundage RC, Schladt DP, Oetting WS, Leduc RE, Israni AK, Guan W, Matas AJ, Jacobson PA.

Pharmacogenomics. 2012 Jul;13(10):1141-7. doi: 10.2217/pgs.12.98.

37.

Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.

Jacobson PA, Schladt D, Israni A, Oetting WS, Lin YC, Leduc R, Guan W, Lamba V, Matas AJ; DeKAF Investigators.

Transplantation. 2012 Mar 27;93(6):624-31. doi: 10.1097/TP.0b013e3182461288.

38.

Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.

Jensen K, Johnson LA, Jacobson PA, Kachler S, Kirstein MN, Lamba J, Klotz KN.

Naunyn Schmiedebergs Arch Pharmacol. 2012 May;385(5):519-25. doi: 10.1007/s00210-011-0719-6. Epub 2012 Jan 17.

39.

Validation of single nucleotide polymorphisms associated with acute rejection in kidney transplant recipients using a large multi-center cohort.

Oetting WS, Schladt DP, Leduc RE, Jacobson PA, Guan W, Matas AJ, Israni A; DeKAF Investigators.

Transpl Int. 2011 Dec;24(12):1231-8. doi: 10.1111/j.1432-2277.2011.01359.x. Epub 2011 Sep 29.

40.

Formation of cyclophosphamide specific DNA adducts in hematological diseases.

Johnson LA, Malayappan B, Tretyakova N, Campbell C, MacMillan ML, Wagner JE, Jacobson PA.

Pediatr Blood Cancer. 2012 May;58(5):708-14. doi: 10.1002/pbc.23254. Epub 2011 Jul 25.

41.

Dosing equation for tacrolimus using genetic variants and clinical factors.

Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA.

Br J Clin Pharmacol. 2011 Dec;72(6):948-57. doi: 10.1111/j.1365-2125.2011.04039.x.

42.

Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.

Jacobson PA, Oetting WS, Brearley AM, Leduc R, Guan W, Schladt D, Matas AJ, Lamba V, Julian BA, Mannon RB, Israni A; DeKAF Investigators.

Transplantation. 2011 Feb 15;91(3):300-8. doi: 10.1097/TP.0b013e318200e991.

43.

Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation.

Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Lamba V, Mannon RB, Julian BA, Israni A; DeKAF investigators.

Transplantation. 2011 Feb 15;91(3):309-16. doi: 10.1097/TP.0b013e318200e971.

44.

Single-nucleotide polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for center-to-center variation.

Israni A, Leduc R, Holmes J, Jacobson PA, Lamba V, Guan W, Schladt D, Chen J, Matas AJ, Oetting WS; DeKAF Investigators.

Transplantation. 2010 Dec 27;90(12):1401-8. doi: 10.1097/TP.0b013e3182000085.

45.

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

Long-Boyle JR, Green KG, Brunstein CG, Cao Q, Rogosheske J, Weisdorf DJ, Miller JS, Wagner JE, McGlave PB, Jacobson PA.

Bone Marrow Transplant. 2011 Jan;46(1):20-6. doi: 10.1038/bmt.2010.53. Epub 2010 Apr 12.

46.

Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.

Jacobson PA, Huang J, Wu J, Kim M, Logan B, Alousi A, Grimley M, Bolaños-Meade J, Ho V, Levine JE, Weisdorf D.

Biol Blood Marrow Transplant. 2010 Mar;16(3):421-9. doi: 10.1016/j.bbmt.2009.11.010.

47.

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, DeVetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D.

Blood. 2009 May 21;113(21):5074-82. doi: 10.1182/blood-2009-02-202937. Epub 2009 Mar 6.

48.

Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.

Johnson L, Orchard PJ, Baker KS, Brundage R, Cao Q, Wang X, Langer E, Farag-El Maasah S, Ross JA, Remmel R, Jacobson PA.

J Clin Pharmacol. 2008 Sep;48(9):1052-62. doi: 10.1177/0091270008321940. Epub 2008 Jul 17.

49.

Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.

Johnson LA, Oetting WS, Basu S, Prausa S, Matas A, Jacobson PA.

Eur J Clin Pharmacol. 2008 Nov;64(11):1047-56. doi: 10.1007/s00228-008-0501-y. Epub 2008 Jun 21.

PMID:
18568343
50.

Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation.

Ibrahim RB, Abidi MH, Ayash LJ, Cronin SM, Cadotte C, Mulawa J, Jacobson PA, Smith DW, Uberti JP, Edwards DJ.

J Oncol Pharm Pract. 2008 Sep;14(3):113-21. doi: 10.1177/1078155208089846. Epub 2008 Jun 13. Erratum in: J Oncol Pharm Pract. 2008 Dec;14(4):233.

PMID:
18556719

Supplemental Content

Loading ...
Support Center